IN2015DN02233A - - Google Patents

Info

Publication number
IN2015DN02233A
IN2015DN02233A IN2233DEN2015A IN2015DN02233A IN 2015DN02233 A IN2015DN02233 A IN 2015DN02233A IN 2233DEN2015 A IN2233DEN2015 A IN 2233DEN2015A IN 2015DN02233 A IN2015DN02233 A IN 2015DN02233A
Authority
IN
India
Prior art keywords
dendrimer
macromolecule
eye
salt
generations
Prior art date
Application number
Other languages
English (en)
Inventor
Jacinth Kincaid; Fairley
Colin Paul; Barrett
Jeremy Robert Arthur; Paull
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Publication of IN2015DN02233A publication Critical patent/IN2015DN02233A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/795Polymers containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2233DEN2015 2012-09-13 2013-09-13 IN2015DN02233A (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261700714P 2012-09-13 2012-09-13
PCT/US2013/059810 WO2014043576A1 (en) 2012-09-13 2013-09-13 Method of treatment or prophylaxis of infections of the eye

Publications (1)

Publication Number Publication Date
IN2015DN02233A true IN2015DN02233A (enrdf_load_html_response) 2015-08-21

Family

ID=50278734

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2233DEN2015 IN2015DN02233A (enrdf_load_html_response) 2012-09-13 2013-09-13

Country Status (9)

Country Link
US (2) US10149885B2 (enrdf_load_html_response)
EP (1) EP2895161B1 (enrdf_load_html_response)
JP (2) JP6419701B2 (enrdf_load_html_response)
CN (2) CN105007910B (enrdf_load_html_response)
CA (1) CA2884897C (enrdf_load_html_response)
DK (1) DK2895161T3 (enrdf_load_html_response)
ES (1) ES2633778T3 (enrdf_load_html_response)
IN (1) IN2015DN02233A (enrdf_load_html_response)
WO (1) WO2014043576A1 (enrdf_load_html_response)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008006A2 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
RU2667118C1 (ru) * 2017-11-15 2018-09-14 Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" Универсальное средство в виде мази для комплексного лечения глазных болезней животных и способ его получения
CN110664757B (zh) * 2018-11-19 2022-08-02 成都瑞沐生物医药科技有限公司 纳米晶滴眼剂、其制备方法及其应用
EP3930730A4 (en) * 2020-04-15 2022-05-11 Starpharma Pty Limited PROPHYLAXIS FOR CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM623994A0 (en) 1994-06-15 1994-07-07 Biomolecular Research Institute Limited Antiviral dendrimers
DK1096934T3 (da) * 1998-07-14 2005-11-28 Pharmacia & Upjohn Co Llc Oxazolidinoner til behandling af öjeninfektioner
AUPP584298A0 (en) * 1998-09-14 1998-10-08 Starpharma Limited Antimicrobial and antiparasitic agents
AUPR412801A0 (en) * 2001-03-30 2001-05-03 Starpharma Limited Agent for the prevention and treatment of sexually transmitted disease s - I
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
CA2562356A1 (en) 2004-04-08 2005-10-27 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids
CA2626105C (en) * 2005-10-18 2015-08-18 Starpharma Pty Limited Microbicidal dendrimer composition delivery system
CA2626865C (en) * 2005-10-25 2014-12-30 Starpharma Pty Limited Macromolecular compounds having controlled stoichiometry
NZ573013A (en) * 2006-05-31 2010-10-29 Medihoney Pty Ltd Medicinal compositions containing honey
US10463609B2 (en) * 2007-10-05 2019-11-05 Wayne State University Dendrimers for sustained release of compounds
EP3246048B1 (en) * 2009-02-18 2024-04-03 Calm Water Therapeutics LLC Bi-functional co-polymer use for ophthalmic applications
US8802654B2 (en) * 2009-07-07 2014-08-12 Adenovir Pharma Ab Antiviral compounds
PL2709633T3 (pl) 2011-05-16 2020-03-31 Starpharma Pty Ltd Sposób leczenia lub profilaktyki waginozy bakteryjnej

Also Published As

Publication number Publication date
US11219691B2 (en) 2022-01-11
WO2014043576A1 (en) 2014-03-20
DK2895161T3 (en) 2017-08-21
CN105007910A (zh) 2015-10-28
US20150238557A1 (en) 2015-08-27
US10149885B2 (en) 2018-12-11
CN108452316B (zh) 2022-04-15
EP2895161A1 (en) 2015-07-22
EP2895161A4 (en) 2016-03-23
JP6419701B2 (ja) 2018-11-07
CA2884897C (en) 2021-07-27
JP2015528509A (ja) 2015-09-28
JP6766114B2 (ja) 2020-10-07
EP2895161B1 (en) 2017-05-03
CN108452316A (zh) 2018-08-28
US20190070249A1 (en) 2019-03-07
CA2884897A1 (en) 2014-03-20
HK1212619A1 (en) 2016-06-17
CN105007910B (zh) 2019-03-19
JP2019001827A (ja) 2019-01-10
ES2633778T3 (es) 2017-09-25

Similar Documents

Publication Publication Date Title
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
EA201201648A1 (ru) Стимуляторы sgc
NZ607600A (en) Compositions for the treatment of diseases
NZ721175A (en) Syk inhibitors
MX349159B (es) Derivados deuterados de ivacaftor.
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
HK1212207A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
NZ715747A (en) Syk inhibitors
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
MY161233A (en) Bis (fluoroalkyl)-1, 4-benzodiazepinone compounds
MA33939B1 (fr) 5-alcynyl-pyrimidines
MX2015008187A (es) Inhibidores de alk deuterados.
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EA201691044A1 (ru) Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
EA201892726A1 (ru) Дейтерированный палбоциклиб
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
SG10201900541QA (en) Derivatives of xanthone compounds
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
MX2016003238A (es) Composiciones antisepticas cationicas.
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
MX2015015755A (es) Derivados de perhidroquinoxalina utiles como analgesicos.
IN2015DN02233A (enrdf_load_html_response)